Explore our corporate updates and press releases below. For the latest news, follow us on LinkedIn.
To learn more about our company, visit our Corporate Overview page. To see our progress toward new answers and disease-centric therapies, visit our Pipeline page or review recent articles and studies on our Publications page.
|03/18/2022||Ichnos Sciences Presents Preclinical Data Package on First-in-class Oncology Treatment, ISB 1442, at IO360 Conference||Press Release|
|03/01/2022||Ichnos Sciences Welcomes Eugene Zhukovsky, Ph.D., as New Chief Scientific Officer||Press Release|
|02/28/2022||Ichnos Sciences Announces Formation of Scientific Advisory Board to Inform Research and Development Strategy in Immuno-Oncology||Press Release|
|02/10/2022||February 2022 Update||Corporate Update|
|12/16/2021||Scrip: Ichnos Gets Going With Almirall Deal, Multiple Myeloma Bispecifics Add Sheen||Media|
|12/14/2021||Ichnos Sciences and Almirall Enter Into a Licensing Agreement for First-In-Class IL-1RAP Antagonist Monoclonal Antibody||Press Release|
|12/11/2021||ISB 1442 Preclinical Data Summary: First-in-Class CD38 and CD47 Bispecific Antibody Innate Cell Modulator for Relapsed / Refractory Multiple Myeloma||Data Presentation|
|12/11/2021||Ichnos Sciences Presents Preclinical Data On Novel ISB 1442 In Relapsed/Refractory Multiple Myeloma At The ASH 2021 Annual Meeting||Press Release|
|11/11/2021||November 2021 Update||Corporate Update|
|11/09/2021||Ichnos Sciences Appoints Sonia Quaratino, M.D., PH.D., to its Board Of Directors||Press Release|
The link above is provided for your convenience, and Ichnos is not responsible for content, privacy, or security issues associated with your visit to external websites.